Author

Naisargee Shah

Observed name: N. Shah

Observed institution: Puma Biotechnology (United States)

OpenAlex ID: A5082563712

MANTRA: A randomized, multicenter, phase 3 study of the MDM2 inhibitor milademetan versus trabectedin in patients with de-differentiated liposarcomas.

2022 · Mrinal M. Gounder, Gary K. Schwartz, et al. · Journal of Clinical Oncology · 9

A phase 2 study of the MDM2 inhibitor milademetan in patients with TP53-wild type and MDM2-amplified advanced or metastatic solid tumors (MANTRA-2).

2022 · Ecaterina Elena Dumbrava, Glenn J. Hanna, et al. · Journal of Clinical Oncology · 7

Neratinib efficacy in a subgroup of patients with EGFR exon 18-mutant non-small cell lung cancer (NSCLC) and central nervous system (CNS) involvement: Findings from the SUMMIT basket trial.

2021 · Jonathan Wade Goldman, Santiago Viteri Ramirez, et al. · Journal of Clinical Oncology · 5

Abstract PS13-20: Bringing diarrhea under CONTROL: Dose escalation reduces neratinib-associated diarrhea and improves tolerability in HER2-positive early-stage breast cancer

2021 · Manuel Ruiz-Borrego, Arlene Chan, et al. · Cancer Research · 5

Dose escalation for mitigating diarrhea: Ranked tolerability assessment of anti-diarrheal regimens in patients receiving neratinib for early-stage breast cancer.

2021 · Gavin M. Marx, Amy Jo Chien, et al. · Journal of Clinical Oncology · 4

OA04.06 Neratinib in Pretreated EGFR Exon 18-Mutant Non-Small Cell Lung Cancer (NSCLC): Initial Findings From the SUMMIT Basket Trial

2021 · V. Boni, C. Dooms, et al. · Journal of Thoracic Oncology · 4

Abstract B034: A phase 2 basket study of the oral MDM2 inhibitor milademetan for MDM2-amplified advanced solid tumors (MANTRA-2)

2023 · Ecaterina E. Dumbrava, Christopher T. Chen, et al. · Molecular Cancer Therapeutics · 1

Preliminary results from a phase 1/1b first-in-human study of BGB-21447, a next-generation BCL2 inhibitor, in patients with B-cell non-Hodgkin lymphoma

2025 · Fei Li, Stephen Opat, et al. · Blood

Abstract CT123: A phase 2 study of the MDM2 inhibitor milademetan in patients with TP53-wild type and MDM2-amplified advanced or metastatic solid tumors (MANTRA-2)

2022 · Ecaterina I. Dumbrava, Glenn J. Hanna, et al. · Cancer Research

Abstract CT235: MANTRA: A randomized, multicenter, phase 3 study of the MDM2 inhibitor milademetan versus trabectedin in patients with de-differentiated liposarcomas

2022 · Mrinal M. Gounder, Gary K. Schwartz, et al. · Cancer Research

Abstract P031: MANTRA: A randomized, multicenter, phase 3 study of the MDM2 inhibitor milademetan (RAIN-32) versus trabectedin in patients with de-differentiated liposarcoma

2021 · Mrinal Gounder, Gary Schwartz, et al. · Molecular Cancer Therapeutics

Works count: 11

Citation count: 35

H-index: 4

I10-index: